Just months after closing a $100 million second fund, Ajax Health announced this morning it has raised another $100 million to form Ajax 3.
HealthQuest Capital led the funding, which included participation from Polaris Partners. According to MassDevice.com, in May 2017 KKR and Aisling Capital teamed up to form Ajax, tapping Spirox chairman & CEO Duke Rohlen to run it. Ajax describes itself as a privately held clinical-stage platform company focused on developing medical technologies.
In a press release, the Menlo Park, Calif.-based company said it will use the capital to invest in companies in the areas of medtech, healthcare services, and healthcare IT “that focus on truly innovative approaches to addressing major issues in healthcare.”
In April, Ajax Health announced an $85 million Fund 2. Then in June, the company said it added another $15 million to that fund, bringing the total to $100 million.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Also in April, Ajax Health led a $21.5 million Series A investment in Ablacon, a Colorado-based provider of AI-guided atrial fibrillation therapies.
“There is a significant need in the medical device space not only for capital but also for operational expertise and guidance,” Rohlen was quoted by MassDevice.com as saying at the time. “With Ajax Health, we are eager to provide the resources necessary to enable companies to provide innovative medical treatments for the millions of people who need them.”
Ajax Health itself closed in June 2018 an oversubscribed $120 million Series B round of funding. New investors included ICONIQ Capital, HealthQuest Capital, Polaris Partners, WTI, and other individual and large family office investors. Majority investor KKR and existing investor Aisling Capital also participated in the financing.
Date: October 08, 2019